Key facts
- It has raised $1.1M across 1 recorded rounds; the latest was Seed Round ($1.1M) in Sep 2025.
- Notable investors include BroadOak Capital Partners.
- Carolina Molecular has filed 1 Form D with the SEC, most recently Nov 2025 ($1.1M sold to 8 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Carolina Molecular
Funding rounds
1 roundsAbout Carolina Molecular
Provider of molecular testing services intended for clinical diagnostics, discovery research, and product development. The company offers customizable assay development, broad-spectrum pathogen detection, and advanced genetic analysis tools, enabling research institutions and technology developers to enhance diagnostic precision, accelerate research timelines, and integrate scalable testing workflows across diverse biomedical applications.
- Sector
- Healthcare
- HQ
- Morrisville, NC, United States
- Founded
- 2025
- Website
- carolinamolecular.com/
- Ownership
- Privately Held (backing)
Carolina Molecular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Carolina Molecular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Carolina Molecular in its N-PORT filings yet. We sweep new filings monthly.